Categories Uncategorized

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) Closer to Pure Mushrooms Sales with Company Code, NPN Submission

  • PULL recently received Company Code from Canada’s Natural and Non-prescription Health Products Directorate
  • Code allows PULL to submit application to sell its first functional mushroom product
  • Company intends to submit additional NPN applications during 2021 as part of larger strategy to develop portfolio of functional mushroom wellness products

Functional mushrooms, those that provide a health benefit beyond just nutrition, are growing in popularity worldwide amid an accelerating trend to fend off viruses with immune-boosting food and drinks. Looking to seize part of a global functional mushroom market forecast by Data Bridge Market Research to hit $555.9 billion by 2028, Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) is checking the boxes to soon commercialize its new line of products.

Pure Extracts, a diversified plant-based extraction company with reach into cannabis, hemp, functional mushrooms and the burgeoning psychedelics sector, recently received a Company Code from Canada’s Natural and Non-prescription Health Products Directorate (“NNHPD”), an important step in moving towards sales. The code allowed the Company to submit an application for a Class 1 Natural Product Number, or NPN for short, for its first functional mushroom product.

Products that receive an 8-digit NPN have been assessed by Health Canada and deemed to be safe, effective and of high quality under the recommended conditions of use. Once approved, the NPN is added to the Licensed Natural Health Products Database where information about the product is available for viewing. The database includes information on a variety of natural health products, such as vitamin supplements, herb and plant-based remedies, probiotics, traditional medicines and more.

Pure Extracts intends to submit additional NPN applications during 2021 as part of its strategy to develop a portfolio of functional mushroom wellness products to sell through Pure Mushrooms Corp., its new, 100%-owned, subsidiary. Pure Mushrooms will employ a direct-to-consumer model, selling its goods through an e-Commerce portal being designed while the licensing process is under way. The new products will be sold under the “Pure Mushrooms” moniker.

Initially, the Company will work with a co-packer to meet consumer demand for Pure Mushrooms products while it explores optimizing existing extraction equipment at its state-of-the-art processing facility outside of Whistler, British Columbia. Planning ahead, Pure Extracts, which holds a Standard Processing License from Health Canada allowing it to manufacture cannabis goods, had its purpose-built facility constructed to meet Good Manufacturing Practices standards of the European Union, aligning for future global distribution of products and formulations were allowed by law.

Pure Extracts CEO Ben Nikolaevsky commented that his team is excited about the milestones ahead to enter the functional mushroom wellness sector that is experiencing “tremendous growth and consumer awareness.” He added that the company expects sales of the new products to begin by the end of this quarter.

For more information, visit the company’s website at www.PureExtractsCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Files Abbreviated New Drug Application for Preservative-Free IV Ketamine NRX-100 Amid Ongoing Shortage

The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is…

1 week ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a…

2 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Announces $10.3 Million Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval

Subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital. Combined…

3 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition

Kadima Neuropsychiatry Institute is expected to become the clinical model for HOPE Therapeutics’ nationwide network…

4 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Is ‘One to Watch’

NRx Pharmaceuticals is advancing a pipeline of innovative therapies targeting multibillion-dollar unmet needs in central…

1 month ago

Republican Lawmakers Embrace Psychedelic Therapies in Shift Toward Veteran Mental Health Reform

Rep. Morgan Luttrell (R-Texas), a retired Navy SEAL, is part of a rising wave of…

1 month ago